LLT1’s high expression within the GC, and its association with proliferating cells, suggests its use as a potential aid for the clinical diagnosis of B cell lymphomas, in particular non–Hodgkin lymphomas, which represent 4–5% of all cancers diagnosed (66). Here, CLEC2D is linked to cancer.